News

Darolutamide (CAS 1297538-32-9), chemically designated as N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide, is a nonsteroidal androgen receptor (AR) antagonist developed by Bayer and Orion Corporation for the treatment of prostate cancer.

Cosperpharm supplies a comprehensive range of aromatic rings and aromatic heterocyclic systems for pharmaceutical, agrochemical, and fine chemical applications.

Cosperpharm supplies a broad portfolio of long-chain alkyl alcohols and ketones for pharmaceutical, cosmetic, and industrial applications. Our range covers saturated and unsaturated fatty alcohols.

This product portfolio comprises eight chemically defined building blocks positioned along the industrial synthesis of Enzalutamide (Xtandi®), a second-generation androgen receptor antagonist approved for metastatic castration-resistant prostate cancer.

This product portfolio comprises four chemically defined building blocks positioned along the industrial synthesis of Bicalutamide (Casodex®), a non-steroidal antiandrogen widely prescribed for prostate cancer.

The three compounds—trans-1,2-Cyclohexanedicarboxylic acid, (1R,2R)-1,2-Cyclohexanedicarboxylic acid, and (1R,2R)-1,2-Cyclohexanedimethanol—represent a progressive synthetic cascade: the racemic trans-diacid serves as the starting material for chiral resolution, the enantiopure (1R,2R)-diacid is the resolved chiral building block, and the (1R,2R)-diol is the reduced, activated form ready for mesylation and final coupling.